155 related articles for article (PubMed ID: 34651438)
21. New C2- and N3-Modified Thieno[2,3-d]Pyrimidine Conjugates with Cytotoxicity in the Nanomolar Range.
Mavrova AT; Dimov S; Yancheva D; Rangelov M; Wesselinova D; Naydenova E
Anticancer Agents Med Chem; 2022; 22(6):1201-1212. PubMed ID: 34315388
[TBL] [Abstract][Full Text] [Related]
22. Hybrid Quinazoline 1,3,5-Triazines as Epidermal Growth Factor Receptor (EGFR) Inhibitors with Anticancer Activity: Design, Synthesis, and Computational Study.
Pathak P; Rimac H; Grishina M; Verma A; Potemkin V
ChemMedChem; 2021 Mar; 16(5):822-838. PubMed ID: 33155373
[TBL] [Abstract][Full Text] [Related]
23. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
24. Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitors.
Li DD; Qin YJ; Sun J; Li JR; Fang F; Du QR; Qian Y; Gong HB; Zhu HL
PLoS One; 2013; 8(8):e69427. PubMed ID: 23936329
[TBL] [Abstract][Full Text] [Related]
25. Recent advances in nitrogen-containing heterocyclic compounds as receptor tyrosine kinase inhibitors for the treatment of cancer: Biological activity and structural activity relationship.
Taruneshwar Jha K; Shome A; Chahat ; Chawla PA
Bioorg Chem; 2023 Sep; 138():106680. PubMed ID: 37336103
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and biological evaluation of novel benzimidazole derivatives as sphingosine kinase 1 inhibitor.
Khairat SHM; Omar MA; Ragab FAF; Roy S; Turab Naqvi AA; Abdelsamie AS; Hirsch AKH; Galal SA; Hassan MI; El Diwani HI
Arch Pharm (Weinheim); 2021 Sep; 354(9):e2100080. PubMed ID: 34128259
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and Anticancer Activity of Benzimidazole/Benzoxazole Substituted Triazolotriazines in Hepatocellular Carcinoma.
Dadashpour S; Küçükkılınç TT; Ercan A; Hosseinimehr SJ; Naderi N; Irannejad H
Anticancer Agents Med Chem; 2019; 19(17):2120-2129. PubMed ID: 31393257
[TBL] [Abstract][Full Text] [Related]
28. The role of EGFR inhibitors in nonsmall cell lung cancer.
Ciardiello F; De Vita F; Orditura M; Tortora G
Curr Opin Oncol; 2004 Mar; 16(2):130-5. PubMed ID: 15075904
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Anticancer and Epidermal Growth Factor Receptor Inhibition Activity by Benzochromeno Pyrimidin Derivatives in Three Human Cancer Cell Lines.
Mohammadian R; Ardestani SK; Safavi M
Med Chem; 2022; 18(6):710-723. PubMed ID: 34819010
[TBL] [Abstract][Full Text] [Related]
30. Recent Progress of Benzimidazole Hybrids for Anticancer Potential.
Akhtar MJ; Yar MS; Sharma VK; Khan AA; Ali Z; Haider MDR; Pathak A
Curr Med Chem; 2020; 27(35):5970-6014. PubMed ID: 31393240
[TBL] [Abstract][Full Text] [Related]
31. Repurposing of Benzimidazole Scaffolds for HER2 Positive Breast Cancer Therapy: An
Jubie S; Durai U; Latha S; Ayyamperumal S; Wadhwani A; Prabha T
Curr Drug Res Rev; 2021; 13(1):73-83. PubMed ID: 32955008
[TBL] [Abstract][Full Text] [Related]
32. A Review: Discovering 1,3,4-oxadiazole and Chalcone Nucleus for Cytotoxicity / EGFR Inhibitory Anticancer Activity.
Patil S; Bhandari S
Mini Rev Med Chem; 2022; 22(5):805-820. PubMed ID: 34477516
[TBL] [Abstract][Full Text] [Related]
33. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy.
Ayati A; Moghimi S; Salarinejad S; Safavi M; Pouramiri B; Foroumadi A
Bioorg Chem; 2020 Jun; 99():103811. PubMed ID: 32278207
[TBL] [Abstract][Full Text] [Related]
34. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
35. 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity.
Liu F; Tang B; Liu H; Li L; Liu G; Cheng Y; Xu Y; Chen W; Huang Y
Anticancer Agents Med Chem; 2016; 16(12):1652-1664. PubMed ID: 27039919
[TBL] [Abstract][Full Text] [Related]
36. Design, Synthesis and Antiproliferative Evaluation of Novel 1,2,4-Triazole/Schiff Base Hybrids with EGFR and B-RAF Inhibitory Activities.
El-Sherief HAM; Youssif BGM; Abdelazeem AH; Abdel-Aziz M; Abdel-Rahman HM
Anticancer Agents Med Chem; 2019; 19(5):697-706. PubMed ID: 30582484
[TBL] [Abstract][Full Text] [Related]
37. Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents.
Ghosh S; Liu XP; Zheng Y; Uckun FM
Curr Cancer Drug Targets; 2001 Aug; 1(2):129-40. PubMed ID: 12188886
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis, and biological evaluation of novel 3-(thiophen-2-ylthio)pyridine derivatives as potential multitarget anticancer agents.
Xi JJ; He RY; Zhang JK; Cai ZB; Zhuang RX; Zhao YM; Shao YD; Pan XW; Shi TT; Dong ZJ; Liu SR; Kong LM
Arch Pharm (Weinheim); 2019 Aug; 352(8):e1900024. PubMed ID: 31338897
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of novel heptamethine cyanine dye-erlotinib conjugates as antitumor agents.
Yang X; Hou Z; Wang D; Mou Y; Guo C
Bioorg Med Chem Lett; 2020 Dec; 30(23):127557. PubMed ID: 32949719
[TBL] [Abstract][Full Text] [Related]
40. HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors.
Gusenbauer S; Vlaicu P; Ullrich A
Oncogene; 2013 Aug; 32(33):3846-56. PubMed ID: 23045285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
